{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:48:27Z","timestamp":1792788507228,"version":"4.5.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Cancerforskningfonden i Norrland","award":["AMP 24-1154"],"award-info":[{"award-number":["AMP 24-1154"]}],"id":[{"id":"https:\/\/ror.org\/0588g3n92","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Bengt Ihre Research Fellowship Grant"},{"name":"Lion\u2019s Research Fund, Link\u00f6ping and Region \u00d6sterg\u00f6tland","award":["R\u00d6-1006094"],"award-info":[{"award-number":["R\u00d6-1006094"]}],"id":[{"id":"https:\/\/ror.org\/024emf479","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Lion\u2019s Research Fund, Link\u00f6ping and Region \u00d6sterg\u00f6tland","award":["R\u00d6-1023270"],"award-info":[{"award-number":["R\u00d6-1023270"]}],"id":[{"id":"https:\/\/ror.org\/024emf479","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Region V\u00e4sterbotten","award":["RV-970069"],"award-info":[{"award-number":["RV-970069"]}]},{"name":"Region V\u00e4sterbotten","award":["RV-979958"],"award-info":[{"award-number":["RV-979958"]}]},{"name":"Region V\u00e4sterbotten","award":["RV-982481"],"award-info":[{"award-number":["RV-982481"]}]},{"name":"Region V\u00e4sterbotten","award":["RV-995863"],"award-info":[{"award-number":["RV-995863"]}]},{"name":"Scandinavia-Japan Sasakawa Foundation","award":["GA24-JPN-0150"],"award-info":[{"award-number":["GA24-JPN-0150"]}]},{"name":"Bengt Ihre Foundation","award":["SLS-885861"],"award-info":[{"award-number":["SLS-885861"]}]},{"name":"Bengt Ihre Foundation","award":["SLS-960529"],"award-info":[{"award-number":["SLS-960529"]}]},{"name":"Bengt Ihre Foundation","award":["SLS-986656"],"award-info":[{"award-number":["SLS-986656"]}]},{"name":"FORSS","award":["FORSS-1013610"],"award-info":[{"award-number":["FORSS-1013610"]}],"id":[{"id":"https:\/\/ror.org\/00brmfv24","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100019970","name":"Lennart Glans Stiftelse","doi-asserted-by":"publisher","award":["990326"],"award-info":[{"award-number":["990326"]}],"id":[{"id":"10.13039\/501100019970","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016669","name":"Sj\u00f6bergstiftelsen","doi-asserted-by":"publisher","award":["LP 23-2337"],"award-info":[{"award-number":["LP 23-2337"]}],"id":[{"id":"10.13039\/100016669","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Umea University","id":[{"id":"https:\/\/ror.org\/05kb8h459","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Targeting Claudin-18 isoform 2 (CLDN18.2) improves survival in CLDN18.2 positive advanced gastric cancer and similar trials on metastatic pancreatic ductal adenocarcinoma (PDAC) are ongoing. Here, we aimed to assess the prevalence of CLDN18.2 positivity in resected PDAC including its association with overall survival (OS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Immunohistochemical analysis on paraffin-embedded primary tumors and lymph node metastases was performed from patients who underwent curative-intent PDAC resection at four centers in Sweden and Finland. In addition, survival outcomes were assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In total, 599 primary tumors and 197 lymph nodes were analyzed. CLDN18.2 positivity was observed in 138 of 599 of primary tumors (23%) and 35 of 197 metastatic lymph nodes (17.8%). CLDN18.2 positivity in primary tumors was associated with higher tumor grade (\n                      <jats:italic>p<\/jats:italic>\n                      = 0.016). Median OS was longer in patients with CLDN18.2-positive tumors (27.7 vs. 21.1 months). Adjusted analysis identified CLDN18.2 positivity as an independent prognostic variable for OS (hazard ratio 0.79; 95% confidence interval 0.64\u20130.98).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>CLDN18.2 is expressed in 23% of primary PDAC tumours, indicating its potential to be used as a therapeutic target in a significant proportion of PDAC patients, and its expression is associated with improved OS in resected PDAC, supporting its role as a prognostic marker.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1245\/s10434-026-20191-5","type":"journal-article","created":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T16:15:57Z","timestamp":1784045757000},"page":"9396-9405","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Prognostic Value of Intratumoral Expression of Claudin 18.2 in Resected Pancreatic Cancer"],"prefix":"10.1245","volume":"33","author":[{"given":"Jun","family":"Yoshino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hakon","family":"Blomstrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Fjellander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Svensson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asif","family":"Halimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ella","family":"Kesti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Sepp\u00e4nen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Vilhav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"\u00d6hlund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caj","family":"Haglund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nils O.","family":"Elander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Naredi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malin","family":"Sund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3777-6887","authenticated-orcid":false,"given":"Oskar","family":"Franklin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,14]]},"reference":[{"issue":"1","key":"20191_CR1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12\u201349. https:\/\/doi.org\/10.3322\/caac.21820.","journal-title":"CA Cancer J Clin."},{"issue":"11","key":"20191_CR2","doi-asserted-by":"publisher","first-page":"2913","DOI":"10.1158\/0008-5472.CAN-14-0155","volume":"74","author":"L Rahib","year":"2014","unstructured":"Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74(11):2913\u201321. https:\/\/doi.org\/10.1158\/0008-5472.CAN-14-0155.","journal-title":"Cancer Res."},{"issue":"21","key":"20191_CR3","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.1200\/JCO.2016.67.5553","volume":"34","author":"AA Khorana","year":"2016","unstructured":"Khorana AA, Mangu PB, Berlin J, Engebretson A, Hong TS, Maitra A, et al. Potentially curable pancreatic cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2016;34(21):2541\u201356. https:\/\/doi.org\/10.1200\/JCO.2016.67.5553.","journal-title":"J Clin Oncol."},{"issue":"17","key":"20191_CR4","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1056\/NEJMra0901557","volume":"362","author":"M Hidalgo","year":"2010","unstructured":"Hidalgo M. Pancreatic cancer. N Engl J Med. 2010;362(17):1605\u201317. https:\/\/doi.org\/10.1056\/NEJMra0901557.","journal-title":"N Engl J Med."},{"key":"20191_CR5","doi-asserted-by":"crossref","unstructured":"Conroy T, Bouch\u00e9 O, B\u00e9couarn Y, Gourgou-Bourgade S, Bennouna J, Khemissa-Akouz F, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011.","DOI":"10.1056\/NEJMoa1011923"},{"issue":"18","key":"20191_CR6","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"DD Von Hoff","year":"2013","unstructured":"Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691\u2013703. https:\/\/doi.org\/10.1056\/NEJMoa1304369.","journal-title":"N Engl J Med."},{"issue":"16","key":"20191_CR7","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1200\/JCO.2006.09.0886","volume":"25","author":"R Herrmann","year":"2007","unstructured":"Herrmann R, Bodoky G, Ruhstaller T, Glimelius B, Bajetta E, Sch\u00fcller J, et al. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol. 2007;25(16):2212\u20137. https:\/\/doi.org\/10.1200\/JCO.2006.09.0886.","journal-title":"J Clin Oncol."},{"key":"20191_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.995357","volume":"12","author":"CM Perell\u00f3-Reus","year":"2022","unstructured":"Perell\u00f3-Reus CM, Rubio-Tom\u00e1s T, Cisneros-Barroso E, Ibarg\u00fcen-Gonz\u00e1lez L, Segura-Sampedro JJ, Morales-Soriano R, et al. Challenges in precision medicine in pancreatic cancer: a focus in cancer stem cells and microbiota. Front Oncol. 2022;12:995357. https:\/\/doi.org\/10.3389\/fonc.2022.995357.","journal-title":"Front Oncol."},{"key":"20191_CR9","doi-asserted-by":"publisher","first-page":"1371421","DOI":"10.3389\/fonc.2024.1371421","volume":"14","author":"Q Xu","year":"2024","unstructured":"Xu Q, Jia C, Ou Y, Zeng C, Jia Y. Dark horse target Claudin 18.2 opens new battlefield for pancreatic cancer. Front Oncol. 2024;14:1371421. https:\/\/doi.org\/10.3389\/fonc.2024.1371421.","journal-title":"Front Oncol."},{"key":"20191_CR10","doi-asserted-by":"publisher","first-page":"1132319","DOI":"10.3389\/fonc.2023.1132319","volume":"13","author":"J Chen","year":"2023","unstructured":"Chen J, Xu Z, Hu C, et al. Targeting CLDN18.2 in cancers of the gastrointestinal tract: new drugs and new indications. Front Oncol. 2023;13:1132319. https:\/\/doi.org\/10.3389\/fonc.2023.1132319.","journal-title":"Front Oncol."},{"issue":"10389","key":"20191_CR11","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/S0140-6736(23)00620-7","volume":"401","author":"K Shitara","year":"2023","unstructured":"Shitara K, Lordick F, Bang YJ, Enzinger P, Ilson D, Shah MA, et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet. 2023;401(10389):1655\u201368. https:\/\/doi.org\/10.1016\/S0140-6736(23)00620-7.","journal-title":"Lancet."},{"issue":"10","key":"20191_CR12","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.14670\/HH-18-477","volume":"37","author":"Z Zhang","year":"2022","unstructured":"Zhang Z, Liu X, Zhou L, Zhang M, Liang Z. Investigation of clinical application of claudin 18 isoform 2 in pancreatic ductal adenocarcinoma: a retrospective analysis of 302 chinese patients. Histol Histopathol. 2022;37(10):1031\u201340. https:\/\/doi.org\/10.14670\/HH-18-477.","journal-title":"Histol Histopathol."},{"issue":"16","key":"20191_CR13","doi-asserted-by":"publisher","first-page":"5394","DOI":"10.3390\/jcm12165394","volume":"12","author":"S Park","year":"2023","unstructured":"Park S, Shin K, Kim IH, Hong T, Kim Y, Suh J, et al. Clinicopathological features and prognosis of resected pancreatic ductal adenocarcinoma patients with claudin-18 overexpression. J C M. 2023;12(16):5394. https:\/\/doi.org\/10.3390\/jcm12165394.","journal-title":"J C M."},{"issue":"3","key":"20191_CR14","doi-asserted-by":"publisher","first-page":"140","DOI":"10.3892\/ol.2025.14886","volume":"29","author":"A Valentini","year":"2025","unstructured":"Valentini A, Arborea G, Grassi I, Savino M, Labarile N, Donghia R, et al. Claudin 18.2: an attractive marker in pancreatic ductal adenocarcinoma. Oncol Lett. 2025;29(3):140. https:\/\/doi.org\/10.3892\/ol.2025.14886.","journal-title":"Oncol Lett."},{"issue":"5","key":"20191_CR15","doi-asserted-by":"publisher","first-page":"543","DOI":"10.5858\/arpa.2020-0032-RA","volume":"145","author":"X Liao","year":"2021","unstructured":"Liao X, Zhang D. The 8th Edition American Joint Committee on Cancer Staging for Hepato-pancreato-biliary cancer: a review and update. Arch Pathol Lab Med. 2021;145(5):543\u201353. https:\/\/doi.org\/10.5858\/arpa.2020-0032-RA.","journal-title":"Arch Pathol Lab Med"},{"key":"20191_CR16","unstructured":"Nagtegaal ID, Odze RD, Klimstra D, et al., eds. WHO classification of tumours of the digestive system. 5th ed. Lyon (France): International Agency for Research on Cancer; 2019."},{"issue":"3","key":"20191_CR17","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1111\/j.1365-2559.2009.03376.x","volume":"55","author":"F Campbell","year":"2009","unstructured":"Campbell F, Smith RA, Whelan P, Sutton R, Raraty M, Neoptolemos JP, et al. Classification of R1 resections for pancreatic cancer: the prognostic relevance of tumour involvement within 1 mm of a resection margin. Histopathology. 2009;55(3):277\u201383. https:\/\/doi.org\/10.1111\/j.1365-2559.2009.03376.x.","journal-title":"Histopathology."},{"issue":"2","key":"20191_CR18","doi-asserted-by":"publisher","first-page":"99","DOI":"10.3892\/ol.2024.14845","volume":"29","author":"H Blomstrand","year":"2024","unstructured":"Blomstrand H, Bodarve M, Groth F, Naredi P, Sund M, Vilhav C, et al. Intratumoural expression of dihydropyrimidine dehydrogenase is an independent prognostic factor in resected pancreatic ductal adenocarcinoma treated with adjuvant gemcitabine. Oncol Lett. 2024;29(2):99. https:\/\/doi.org\/10.3892\/ol.2024.14845.","journal-title":"Oncol Lett."},{"issue":"23","key":"20191_CR19","doi-asserted-by":"publisher","first-page":"7624","DOI":"10.1158\/1078-0432.CCR-08-1547","volume":"14","author":"U Sahin","year":"2008","unstructured":"Sahin U, Koslowski M, Dhaene K, et al. Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development. Clin Cancer Res. 2008;14(23):7624\u201334. https:\/\/doi.org\/10.1158\/1078-0432.CCR-08-1547.","journal-title":"Clin Cancer Res."},{"issue":"19","key":"20191_CR20","doi-asserted-by":"publisher","first-page":"3882","DOI":"10.1158\/1078-0432.CCR-23-0204","volume":"29","author":"SJ Klempner","year":"2023","unstructured":"Klempner SJ, Lee KW, Shitara K, Metges JP, Lonardi S, Ilson DH, et al. ILUSTRO: phase II multicohort trial of zolbetuximab in patients with advanced or metastatic claudin 18.2\u2013positive gastric or gastroesophageal junction adenocarcinoma. Clin Cancer Res. 2023;29(19):3882\u201391. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-0204.","journal-title":"Clin Cancer Res."},{"issue":"6","key":"20191_CR21","doi-asserted-by":"publisher","first-page":"555","DOI":"10.4097\/kjae.2016.69.6.555","volume":"69","author":"DK Lee","year":"2016","unstructured":"Lee DK. Alternatives to P value: confidence interval and effect size. Korean J Anesthesiol. 2016;69(6):555. https:\/\/doi.org\/10.4097\/kjae.2016.69.6.555.","journal-title":"Korean J Anesthesiol."},{"issue":"15","key":"20191_CR22","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1002\/sim.3618","volume":"28","author":"IR White","year":"2009","unstructured":"White IR, Royston P. Imputing missing covariate values for the Cox model. Stat Med. 2009;28(15):1982\u201398. https:\/\/doi.org\/10.1002\/sim.3618.","journal-title":"Stat Med."},{"key":"20191_CR23","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1080\/19312450709336664","volume":"1","author":"AF Hayes","year":"2007","unstructured":"Hayes AF, Krippendorff K. Answering the call for a standard reliability measure for coding data. Comm Methods Measures. 2007;1:77\u201389. https:\/\/doi.org\/10.1080\/19312450709336664.","journal-title":"Comm Methods Measures."},{"issue":"1","key":"20191_CR24","doi-asserted-by":"publisher","first-page":"e1523096","DOI":"10.1080\/2162402X.2018.1523096","volume":"8","author":"T. \u04e6zlem","year":"2019","unstructured":"\u04e6zlem T., Mitnacht-Kraus R, W\u00f6ll S, Yamada T, Sahin U. Characterization of zolbetuximab in pancreatic cancer models. OncoImmunology. 2019;8(1):e1523096. https:\/\/doi.org\/10.1080\/2162402X.2018.1523096.","journal-title":"OncoImmunology"},{"issue":"3","key":"20191_CR25","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1002\/ijc.28400","volume":"134","author":"S W\u00f6ll","year":"2014","unstructured":"W\u00f6ll S, Schlitter AM, Dhaene K, et al. Claudin 182 is a target for IMAB362 antibody in pancreatic neoplasms. Int J Cancer. 2014;134(3):731\u20139. https:\/\/doi.org\/10.1002\/ijc.28400.","journal-title":"Int J Cancer."},{"key":"20191_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2025.102362","volume":"55","author":"RJ Arseneau","year":"2025","unstructured":"Arseneau RJ, Kempster E, Bekkers C, Samson T, Gala-Lopez BL, Ramjeesingh R, et al. Claudin 18 (43\u201314A clone) expression in pancreatic ductal adenocarcinoma: Assessment of a potential clinical biomarker for zolbetuximab therapy. Transl Oncol. 2025;55:102362. https:\/\/doi.org\/10.1016\/j.tranon.2025.102362.","journal-title":"Transl Oncol."},{"issue":"5","key":"20191_CR27","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.annonc.2021.02.005","volume":"32","author":"U Sahin","year":"2021","unstructured":"Sahin U, T\u00fcreci \u00d6, Manikhas G, Lordick F, Rusyn A, Vynnychenko I, et al. FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma. Ann Oncol. 2021;32(5):609\u201319. https:\/\/doi.org\/10.1016\/j.annonc.2021.02.005.","journal-title":"Ann Oncol"},{"issue":"11","key":"20191_CR28","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.3390\/jpm11111095","volume":"11","author":"A Pellino","year":"2021","unstructured":"Pellino A, Brignola S, Riello E, Niero M, Murgioni S, Guido M, et al. Association of CLDN18 protein expression with clinicopathological features and prognosis in advanced gastric and gastroesophageal junction adenocarcinomas. JPM. 2021;11(11):1095. https:\/\/doi.org\/10.3390\/jpm11111095.","journal-title":"JPM."},{"key":"20191_CR29","doi-asserted-by":"publisher","DOI":"10.1200\/PO.23.00543","volume":"8","author":"R Waters","year":"2024","unstructured":"Waters R, Sewastjanow-Silva M, Yamashita K, Abdelhakeem A, Iwata KK, Moran D, et al. Retrospective study of claudin 18 isoform 2 prevalence and prognostic association in gastric and gastroesophageal junction adenocarcinoma. JCO Precis Oncol. 2024;8:e2300543. https:\/\/doi.org\/10.1200\/PO.23.00543.","journal-title":"JCO Precis Oncol."},{"key":"20191_CR30","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s40364-022-00385-1","volume":"10","author":"W Cao","year":"2022","unstructured":"Cao W, Xing H, Li Y, Tian W, Song Y, Jiang Z, et al. Claudin182 is a novel molecular biomarker for tumor-targeted immunotherapy. Biomark Res. 2022;10:38. https:\/\/doi.org\/10.1186\/s40364-022-00385-1.","journal-title":"Biomark Res."},{"key":"20191_CR31","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2025-336277","author":"J Liu","year":"2026","unstructured":"Liu J, Hou X, Li L, Bai W, Zhou T, Chen M, et al. KRAS mutation-driven O-GlcNAcylation of CLDN182 enhances the progression of pancreatic cancer and reduces the efficacy of CLDN18.2-targeted therapy. Gut. 2026. https:\/\/doi.org\/10.1136\/gutjnl-2025-336277.","journal-title":"Gut"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-20191-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-026-20191-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-20191-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T17:52:25Z","timestamp":1789667545000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-026-20191-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,14]]},"references-count":31,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["20191"],"URL":"https:\/\/doi.org\/10.1245\/s10434-026-20191-5","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,14]]},"assertion":[{"value":"3 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Asif Halimi organizes a course in pancreatic surgery, sponsored by Olympus.","order":1,"name":"Ethics","label":"Disclosure","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"This study was approved by the Swedish Ethical Review Authority (DNR: 2021-02787, 2020-01511, 09\u2010175M\/2009\u20101378\u201031, HUS\/1223\/2021).","order":2,"name":"Ethics","label":"Ethics Approval and Consent to Participate","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"All authors have agreed to the publications of this manuscript. Additionally, permission to publish the data in this study was obtained from the relevant institutional review board.","order":3,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Ethics"}}]}}